EUROPE DRY EYE DISEASE MARKET FORECAST 2024-2032
KEY FINDINGS The Europe dry eye disease market is projected to grow at a CAGR of 4.70% during the forecast period from 2024 to 2032. The market was valued at $1686.02 million in 2023, reaching a r... もっと見る
SummaryKEY FINDINGSThe Europe dry eye disease market is projected to grow at a CAGR of 4.70% during the forecast period from 2024 to 2032. The market was valued at $1686.02 million in 2023, reaching a revenue of $2569.11 million by 2032. MARKET INSIGHTS The Europe dry eye disease market is set for consistent growth, driven by the aging population, increasing demand for dry eye disease treatment, and technological advancements in diagnostic and therapeutic products. Also, the region’s dry eye disease market is characterized by the rising prevalence of dry eye disease across various age groups, influenced by lifestyle changes such as increased screen time and exposure to environmental pollutants. REGIONAL ANALYSIS The Europe dry eye disease market growth assessment comprises the analysis of the United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe. In the United Kingdom, increasing awareness of dry eye disease and growing government support are expected to drive market growth. The National Health Service (NHS) provides eye screening programs and helpline services for dry eye treatment. Additionally, ongoing research on dry eye disease in the UK further enhances growth prospects. In France, market expansion is driven by a growing number of treatment options and an increasing patient population. Additionally, the growing geriatric population is a significant factor, as older individuals are more susceptible to conditions that impact tear production, leading to higher rates of dry eye disease. The rise in conditions like diabetes and autoimmune diseases, which are common dry eye disease causes, also contributes to the expanding patient base. Furthermore, heightened awareness about dry eye disease diagnosis and the availability of more advanced treatment options are pushing the demand for dry eye disease treatment products across the region. Advancements in therapeutic and diagnostic products are enhancing the treatment of dry eye disease. The introduction of innovative dry eye disease treatment drugs and products, such as artificial tears, lubricants, and anti-inflammatory treatments, is improving patient outcomes. Moreover, the demand for dry eye disease treatment devices is rising as technological innovations in tear production and management devices continue to emerge. SEGMENTATION ANALYSIS The Europe dry eye disease market segmentation includes distribution channel, type, dosage, and product. The distribution channel segment is further divided into hospital pharmacies, online pharmacies/stores, and independent pharmacies and drugstores. Retail pharmacies are independent establishments licensed to provide medications to the public. Over-the-counter (OTC) products form a key part of this distribution channel, making retail pharmacies a popular one-stop destination for these medications. The cost of OTC drugs at retail pharmacies is typically lower than those found in hospital pharmacies, providing an additional incentive for consumers to choose independent outlets. Moreover, the retail pharmacy industry offers a seamless omnichannel experience, including home delivery services. There is also a growing trend towards in-home pharmacy services, as consumers prioritize convenience and explore digital-first pharmacy options, particularly in the wake of COVID-19. Many drugstores and small pharmacies are shifting from traditional models to technology-enabled ones, moving from in-person pickups to delivery services, which is expected to boost the growth of independent pharmacies. Additionally, the increasing prevalence of dry eye disease is leading to more hospital visits, driving the demand for dry eye disease medications through hospital pharmacies. Pharmacists generally collaborate with other pharmacies to source supplies; however, in Eastern Europe, wholesalers are the main suppliers of pharmaceuticals. In contrast, in Western Europe, hospital pharmacists often procure supplies directly from manufacturers. COMPETITIVE INSIGHTS Some of the eminent market players in the Europe dry eye disease market are Santen Pharmaceutical Co Ltd, Novartis AG, Oasis Medical, etc. Novartis AG is a Swiss-American multinational pharmaceutical company specializing in products for gene and cell therapies, as well as treatments for cancer, metabolic, and cardiovascular conditions. Its product portfolio includes biosimilars, generic medicines, vision care products, and ophthalmic pharmaceuticals. The company has a global presence, operating in regions such as the Middle East & Africa, the Americas, Europe, and Asia-Pacific, with its headquarters located in Basel, Switzerland. One of its notable products, Xiidra® (lifitegrast ophthalmic solution) 5%, is the only prescription treatment approved to address the symptoms and signs of dry eye disease by inhibiting inflammation associated with the condition. Table of ContentsTABLE OF CONTENTS1. RESEARCH SCOPE & METHODOLOGY 1.1. STUDY OBJECTIVES 1.2. METHODOLOGY 1.3. ASSUMPTIONS & LIMITATIONS 2. EXECUTIVE SUMMARY 2.1. MARKET SIZE & ESTIMATES 2.2. MARKET OVERVIEW 2.3. SCOPE OF STUDY 2.4. CRISIS SCENARIO ANALYSIS 2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET 2.5. MAJOR MARKET FINDINGS 2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE 2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE 2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS 2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES 3. MARKET DYNAMICS 3.1. KEY DRIVERS 3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS 3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE 3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE 3.2. KEY RESTRAINTS 3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS 3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES 3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE 4. KEY ANALYTICS 4.1. PARENT MARKET ANALYSIS 4.2. KEY MARKET TRENDS 4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE 4.3. PORTER’S FIVE FORCES ANALYSIS 4.3.1. BUYERS POWER 4.3.2. SUPPLIERS POWER 4.3.3. SUBSTITUTION 4.3.4. NEW ENTRANTS 4.3.5. INDUSTRY RIVALRY 4.4. GROWTH PROSPECT MAPPING 4.4.1. GROWTH PROSPECT MAPPING FOR EUROPE DRY EYE DISEASE MARKET 4.5. MARKET MATURITY ANALYSIS 4.6. MARKET CONCENTRATION ANALYSIS 4.7. VALUE CHAIN ANALYSIS 4.7.1. RESEARCH AND DEVELOPMENT 4.7.2. MANUFACTURING 4.7.3. DISTRIBUTORS 4.7.4. POST-SALES MONITORING 5. MARKET BY TYPE 5.1. OTC 5.2. PRESCRIPTION 6. MARKET BY PRODUCT 6.1. ANTI-INFLAMMATORY DRUGS 6.1.1. CYCLOSPORINE 6.1.2. CORTICOSTEROID 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS 6.2. ARTIFICIAL TEARS 6.3. PUNCTAL PLUGS 6.4. SECRETAGOGUES 6.5. OTHER PRODUCTS 7. MARKET BY DOSAGE 7.1. EYE DROPS 7.2. EYE SOLUTIONS 7.3. OINTMENTS 7.4. GELS 7.5. CAPSULES & TABLETS 8. MARKET BY DISTRIBUTION CHANNEL 8.1. HOSPITAL PHARMACIES 8.2. INDEPENDENT PHARMACIES AND DRUG STORES 8.3. ONLINE PHARMACIES/STORES 9. GEOGRAPHICAL ANALYSIS 9.1. EUROPE 9.1.1. MARKET SIZE & ESTIMATES 9.1.2. EUROPE DRY EYE DISEASE MARKET DRIVERS 9.1.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES 9.1.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK 9.1.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET 9.1.6. COUNTRY ANALYSIS 9.1.6.1.1. UNITED KINGDOM 9.1.6.1.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 9.1.6.2. GERMANY 9.1.6.2.1.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 9.1.6.3. FRANCE 9.1.6.3.1.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 9.1.6.4. ITALY 9.1.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 9.1.6.5. SPAIN 9.1.6.5.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 9.1.6.6. BELGIUM 9.1.6.6.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 9.1.6.7. POLAND 9.1.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 9.1.6.8. REST OF EUROPE 9.1.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 10. COMPETITIVE LANDSCAPE 10.1. KEY STRATEGIC DEVELOPMENTS 10.1.1. MERGERS & ACQUISITIONS 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS 10.1.3. PARTNERSHIPS & AGREEMENTS 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES 10.2. COMPANY PROFILES 10.2.1. ALCON 10.2.1.1. COMPANY OVERVIEW 10.2.1.2. PRODUCT LIST 10.2.1.3. STRENGTHS & CHALLENGES 10.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE) 10.2.2.1. COMPANY OVERVIEW 10.2.2.2. PRODUCT LIST 10.2.2.3. STRENGTHS & CHALLENGES 10.2.3. BAUSCH HEALTH COMPANIES INC 10.2.3.1. COMPANY OVERVIEW 10.2.3.2. PRODUCT LIST 10.2.3.3. STRENGTHS & CHALLENGES 10.2.4. JOHNSON & JOHNSON 10.2.4.1. COMPANY OVERVIEW 10.2.4.2. PRODUCT LIST 10.2.4.3. STRENGTHS & CHALLENGES 10.2.5. AFT PHARMACEUTICALS 10.2.5.1. COMPANY OVERVIEW 10.2.5.2. PRODUCT LIST 10.2.5.3. STRENGTHS & CHALLENGES 10.2.6. LUMENIS 10.2.6.1. COMPANY OVERVIEW 10.2.6.2. PRODUCT LIST 10.2.6.3. STRENGTHS & CHALLENGES 10.2.7. NOVALIQ GMBH 10.2.7.1. COMPANY OVERVIEW 10.2.7.2. PRODUCT LIST 10.2.7.3. STRENGTHS & CHALLENGES 10.2.8. OASIS MEDICAL 10.2.8.1. COMPANY OVERVIEW 10.2.8.2. PRODUCTS LIST 10.2.8.3. STRENGTHS & CHALLENGES 10.2.9. OTSUKA PHARMACEUTICAL CO LTD 10.2.9.1. COMPANY OVERVIEW 10.2.9.2. PRODUCT LIST 10.2.9.3. STRENGTHS & CHALLENGES 10.2.10. SANTEN PHARMACEUTICAL CO LTD 10.2.10.1. COMPANY OVERVIEW 10.2.10.2. PRODUCTS LIST 10.2.10.3. STRENGTHS & CHALLENGES 10.2.11. NOVARTIS AG 10.2.11.1. COMPANY OVERVIEW 10.2.11.2. PRODUCT LIST 10.2.11.3. STRENGTHS & CHALLENGES 10.2.12. SENTISS PHARMA PRIVATE LIMITED 10.2.12.1. COMPANY OVERVIEW 10.2.12.2. PRODUCTS LIST 10.2.12.3. STRENGTHS & CHALLENGES 10.2.13. TEVA PHARMACEUTICAL INDUSTRIES LTD 10.2.13.1. COMPANY OVERVIEW 10.2.13.2. PRODUCT LIST 10.2.13.3. STRENGTHS & CHALLENGES 10.2.14. SUN PHARMACEUTICAL INDUSTRIES LTD 10.2.14.1. COMPANY OVERVIEW 10.2.14.2. PRODUCT LIST 10.2.14.3. STRENGTHS & CHALLENGES 10.2.15. VISUFARMA 10.2.15.1. COMPANY OVERVIEW 10.2.15.2. PRODUCT LIST 10.2.15.3. STRENGTHS & CHALLENGES
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポートInkwood Research 社の最新刊レポート本レポートと同じKEY WORD(dry eye)の最新刊レポートよくあるご質問Inkwood Research社はどのような調査会社ですか?Inkwood Researchは世界40ヶ国以上の国を対象に広範な市場を調査し、世界市場全体を調査したレポートに加え、アジア太平洋地域、欧州、北米などの主要地域や主要国毎のレポートも数多く出版してい... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/15 10:26 150.67 円 164.75 円 199.57 円 |